Pharming Group N.V. Files Form 6-K

Ticker: PHAR · Form: 6-K · Filed: 2025-10-06T00:00:00.000Z

Sentiment: neutral

Topics: 6-K, press-release, regulatory-filing

TL;DR

Pharming Group N.V. filed a 6-K on Oct 6, 2025, likely with a press release. Check it for updates.

AI Summary

Pharming Group N.V. filed a Form 6-K on October 6, 2025, to furnish a press release dated October 6, 2025. The filing does not contain specific financial figures or operational updates beyond the provision of this press release.

Why It Matters

This filing indicates Pharming Group N.V. is providing an update, likely through the attached press release, which could contain important business or financial information for investors.

Risk Assessment

Risk Level: low — This is a routine filing (Form 6-K) to furnish a press release, not a report with significant new financial data or strategic changes.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose of this Form 6-K filing is to furnish a press release dated October 6, 2025, as required for foreign private issuers.

What is the filing date of this Form 6-K?

This Form 6-K was filed on October 6, 2025.

What is the exact name of the registrant?

The exact name of the registrant is Pharming Group N.V.

What is the principal executive office address of Pharming Group N.V.?

The principal executive offices are located at Darwinweg 24, 2333 CR Leiden, The Netherlands.

Which exhibit is furnished with this Form 6-K?

Exhibit 99.1, a press release of Pharming Group N.V., is furnished with this Form 6-K.

From the Filing

0001828316-25-000045.txt : 20251006 0001828316-25-000045.hdr.sgml : 20251006 20251006114549 ACCESSION NUMBER: 0001828316-25-000045 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20251006 FILED AS OF DATE: 20251006 DATE AS OF CHANGE: 20251006 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharming Group N.V. CENTRAL INDEX KEY: 0001828316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39822 FILM NUMBER: 251376113 BUSINESS ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR BUSINESS PHONE: 31 (0)71 5247 400 MAIL ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR FORMER COMPANY: FORMER CONFORMED NAME: Pharming Group Group N.V. DATE OF NAME CHANGE: 20201014 6-K 1 pharminggroupprovidesupdat.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-39822 Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated October 6, 2025. EXHIBIT INDEX Exhibit No. Description 99.1 Pharming Group provides update on previously announced G&A expense reduction plan SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pharming Group N.V. By: /s/ Fabrice Chouraqui Name: Fabrice Chouraqui Title: CEO Date: October 6, 2025 Pharming Group provides update on previously announced G&A expense reduction plan Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced the implementation of an organizational restructuring to accelerate the Company’s growth. The restructuring is aligned with our previously announced plan to reduce general and administrative (G&A) expenses to optimize capital allocation across the organization. The restructuring includes a redesign of Pharming’s organizational structure and a 20% net reduction in non-commercial and non-medical headcount, primarily at our Netherlands headquarters. We remain on track to reduce total G&A expenses by 15% or US$10 million annually and anticipate one-time restructuring costs of approximately $7 million to be recorded in the fourth quarter of 2025 in connection with the headcount reduction. Pharming has consulted with its Dutch Works Council over the past several months, in accordance with Dutch labor law, regarding the organizational changes. About Pharming Group N.V. Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its em

View on Read The Filing